Abbott
Abbott Laboratories, commonly known as Abbott, is a leading global healthcare company headquartered in the United States. Founded in 1888, Abbott has established a strong presence in various operational regions, including North America, Europe, and Asia. The company operates primarily in the medical devices, diagnostics, nutrition, and pharmaceuticals sectors. Abbott is renowned for its innovative products, such as the FreeStyle Libre glucose monitoring system and Similac infant formula, which set industry standards for quality and effectiveness. With a commitment to advancing health and well-being, Abbott has achieved significant milestones, including the rapid development of COVID-19 testing solutions. As a market leader, Abbott consistently ranks among the top healthcare companies worldwide, recognised for its dedication to research and development, and its ability to deliver cutting-edge solutions that improve patient outcomes.
DitchCarbon Score
How does Abbott's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbott's score of 52 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Abbott's reported carbon emissions
In 2023, Abbott reported total greenhouse gas emissions of approximately 917,000,000 kg CO2e, which includes 510,000,000 kg CO2e from Scope 1 emissions and 407,000,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 30% by 2030, using 2018 as the base year. Additionally, Abbott aims for 82% of its suppliers, based on emissions from purchased goods and services and upstream transportation and distribution, to have science-based targets by 2026. Abbott is committed to achieving net-zero emissions by 2050, encompassing all scopes of emissions. This long-term goal reflects the company's dedication to sustainability and climate action within the healthcare sector. The company has disclosed its emissions data across all relevant scopes, including Scope 3, which accounts for indirect emissions from its value chain. Overall, Abbott's climate commitments and reduction initiatives demonstrate a proactive approach to addressing climate change and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 620,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 648,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbott is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
